Phase II trial of bevacizumab and sorafenib in recurrent ovarian cancer patients with or without prior-bevacizumab treatment

OBJECTIVE: To examine whether blocking multiple points of the angiogenesis pathway by addition of sorafenib, a multi-kinase inhibitor against VEGFR2/3, Raf, c-Kit, and PDGFR, to bevacizumab would yield clinical activity in ovarian cancer (OvCa). METHODS: This phase II study tested bevacizumab plus s...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Gynecol Oncol
Main Authors: Lee, Jung-Min, Annunziata, Christina M., Hays, John L., Cao, Liang, Choyke, Peter, Yu, Minshu, An, Daniel, Turkbey, Ismail Baris, Minasian, Lori M., Steinberg, Seth M., Chen, Helen, Wright, John, Kohn, Elise C.
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7541580/
https://ncbi.nlm.nih.gov/pubmed/32747013
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2020.07.031
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados